🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/01/2010 9,00 9,96 8,94 9,42 +4,67% 11,33% 383.400
12/01/2010 9,24 9,24 8,88 9,00 -3,23% 3,90% 149.650
11/01/2010 9,36 9,42 9,24 9,30 +0,00% 1,92% 97.133
08/01/2010 9,06 9,30 9,06 9,30 +1,97% 2,65% 141.533
07/01/2010 9,00 9,12 8,82 9,12 +1,33% 3,33% 157.267
06/01/2010 9,24 9,30 8,94 9,00 -3,23% 3,90% 143.617
05/01/2010 9,48 9,48 9,12 9,30 -1,90% 3,80% 129.433
04/01/2010 8,88 9,48 8,64 9,48 +8,22% 9,46% 257.533
31/12/2009 8,76 8,88 8,70 8,76 -0,68% 2,05% 182.567
30/12/2009 9,00 9,12 8,70 8,82 -2,65% 4,67% 224.767
29/12/2009 9,12 9,24 8,88 9,06 -1,31% 3,95% 148.867
28/12/2009 9,48 9,66 9,12 9,18 -4,97% 5,70% 180.783
24/12/2009 9,78 9,84 9,36 9,66 -1,83% 4,91% 121.733
23/12/2009 9,84 9,90 9,48 9,84 +1,86% 4,27% 237.033
22/12/2009 9,60 9,72 9,12 9,66 +8,05% 6,25% 611.200
21/12/2009 8,82 9,00 8,70 8,94 +2,76% 3,40% 137.917
18/12/2009 8,82 9,06 8,70 8,70 -0,68% 4,08% 247.517
17/12/2009 8,94 9,06 8,70 8,76 -2,67% 4,03% 132.217
16/12/2009 9,12 9,24 8,88 9,00 -0,66% 3,95% 161.183
15/12/2009 9,24 9,42 9,00 9,06 -1,95% 4,55% 142.000
14/12/2009 9,54 9,54 9,06 9,24 +1,32% 5,03% 113.933
11/12/2009 9,06 9,18 8,88 9,12 +0,66% 3,31% 91.567
10/12/2009 9,24 9,42 8,76 9,06 -1,31% 7,14% 277.967
09/12/2009 9,18 9,30 8,70 9,18 +0,00% 6,54% 151.883
08/12/2009 9,84 9,90 9,18 9,18 -7,27% 7,32% 221.083
07/12/2009 9,90 10,14 9,72 9,90 -0,60% 4,24% 236.883
04/12/2009 9,78 10,08 9,36 9,96 +2,47% 7,36% 206.983
03/12/2009 9,54 10,20 9,54 9,72 +0,62% 6,92% 332.300
02/12/2009 8,64 9,90 8,58 9,66 +11,81% 15,28% 525.083
01/12/2009 8,52 8,70 8,40 8,64 +1,41% 3,52% 114.883